Exane Derivatives Atea Pharmaceuticals, Inc. Call Options Transaction History
Exane Derivatives
- $157 Million
- Q2 2022
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding AVIR
# of Institutions
111Shares Held
51.8MCall Options Held
71.8KPut Options Held
318K-
Black Rock Inc. New York, NY9.12MShares$31.4 Million0.0% of portfolio
-
Bml Capital Management, LLC Zionsville, IN6.65MShares$22.9 Million13.11% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA5.44MShares$18.7 Million0.64% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.72MShares$16.3 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA4.48MShares$15.4 Million1.81% of portfolio
About Atea Pharmaceuticals, Inc.
- Ticker AVIR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,258,600
- Market Cap $286M
- Description
- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...